Cytochrome P450 pharmacogenetics and cancer

Oncogene

Volumn 25, Issue 11, 2006, Pages 1679-1691

  Rodriguez Antona, C ^a   Ingelman Sundberg, M ^b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Anticancer drugs; Carcinogens; Genetic polymorphism; Metabolic activation; Pharmacogenomics; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; CAFFEINE; CARCINOGEN; COUMARIN; CYCLOPHOSPHAMIDE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 ISOENZYME; DISULFIRAM; DOCETAXEL; ETOPOSIDE; EXEMESTANE; FLUOROURACIL; FLUTAMIDE; FULVESTRANT; GEFITINIB; HALOTHANE; IDARUBICIN; IMATINIB; IRINOTECAN; LETROZOLE; METHOXYFLURANE; NICOTINE; OMEPRAZOLE; TAMOXIFEN; TEGAFUR; UNINDEXED DRUG; VALPROIC ACID;

ALLELE; CANCER; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER RISK; CANCER THERAPY; CARCINOGENESIS; DRUG ACTIVATION; DRUG INACTIVATION; DRUG METABOLISM; DRUG TARGETING; DRUG TRANSFORMATION; GENE FUNCTION; GENETIC POLYMORPHISM; HUMAN; NONHUMAN; PHARMACOGENETICS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; XENOBIOTIC METABOLISM;

ANTINEOPLASTIC AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; INCIDENCE; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; XENOBIOTICS;

EID: 33645116164     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1209377     Document Type: Review

References (128)

1. Agundez JA. (2004). Curr Drug Metab 5: 211-224.
2. Aklillu E, Carrillo JA, Makonnen E, Hellman K, Pitarque M, Bertilsson L et al. (2003). Mol Pharmacol 64: 659-669.
3. Aklillu E, Oscarson M, Hidestrand M, Leidvik B, Otter C, Ingelman-Sundberg M. (2002). Mol Pharmacol 61: 586-594.
4. Aklillu E, Ovrebo S, Botnen IV, Otter C, Ingelman-Sundberg M. (2005). Cancer Res 65: 5105-5111.
5. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. (1996). J Pharmacol Exp Ther 278: 441-446.
6. Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y et al. (2002). Cancer Epidemiol Biomarkers Prev 11: 890-894.
7. Bournique B, Lemarie A. (2002). Drug Metab Dispos 30: 1149-1152.
8. Buters J, Quintanilla-Martinez L, Schober W, Soballa VJ, Hintermair J, Wolff T et al. (2003). Carcinogenesis 24: 327-334.
9. Buters JT, Sakai S, Richter T, Pineau T, Alexander DL, Savas U et al. (1999). Proc Natl Acad Sci USA 96: 1977-1982.
10. Chen JK, Capdevila J, Harris RC. (2001). Mol Cell Biol 21: 6322-6331.
11. Clarke R, Liu MC, Bouker KB, Gu Z, Lee RY, Zhu Y et al. (2003). Oncogene 22: 7316-7339.
12. Crewe HK, Notley LM, Wunsch RM, Lennard MS, Gillam EM. (2002). Drug Metab Dispos 30: 869-874.
13. Dachs GU, Tupper J, Tozer GM. (2005). Anticancer Drugs 16: 349-359.
14. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI et al. (2001). Pharmacogenetics 11: 597-607.
15. Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W et al. (2002). Pharmacogenetics 12: 299-306.
16. Dally H, Edler L, Jager B, Schmezer P, Spiegelhalder B, Dienemann H et al. (2003). Pharmacogenetics 13: 607-618.
17. DeMichele A, Aplenc R, Botbyl J, Colligan T, Wray L, Klein-Cabral M et al. (2005). J Clin Oncol 23: 5552-5559.
18. Desta Z, Zhao X, Shin JG, Flockhart DA. (2002). Clin Pharmacokinet 41: 913-958.
19. Dhaini HR, Thomas DG, Giordano TJ, Johnson TD, Biermann JS, Leu K et al. (2003). J Clin Oncol 21: 2481-2485.
20. Downie D, McFadyen MC, Rooney PH, Cruickshank ME, Parkin DE, Miller ID et al. (2005). Clin Cancer Res 11: 7369-7375.
21. Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV et al. (1998). J Pharmacol Exp Ther 286: 1253-1259.
22. Engels FK, Ten Tije AJ, Baker SD, Lee CK, Loos WJ, Vulto AG et al. (2004). Clin Pharmacol Ther 75: 448-454.
23. Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J et al. (1999). J Clin Oncol 17: 1516-1525.
24. Gambier N, Batt AM, Marie B, Pfister M, Siest G, Visvikis-Siest S. (2005). Pharmacogenomics J 5: 271-275.
25. Gervot L, Rochat B, Gautier JC, Bohnenstengel F, Kroemer H, de Berardinis V et al. (1999). Pharmacogenetics 9: 295-306.
26. Gharavi N, El-Kadi AO. (2004). Curr Drug Metab 5: 203-210.
27. Gibson P, Gill JH, Khan PA, Seargent JM, Martin SW, Batman PA et al. (2003). Mol Cancer Ther 2: 527-534.
28. Goh BC, Lee SC, Wang LZ, Fan L, Guo JY, Lamba J et al. (2002). J Clin Oncol 20: 3683-3690.
29. Gonzalez FJ. (2003). Drug Metab Rev 35: 319-335.
30. Goodwin B, Moore LB, Stoltz CM, McKee DD, Kliewer SA. (2001). Mol Pharmacol 60: 427-431.
31. Goria-Gatti L, Iannone A, Tomasi A, Poli G, Albano E. (1992). Carcinogenesis 13: 799-805.
32. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K et al. (2005). Clin Cancer Res 11: 4430-4436.
33. Guengerich FP, Parikh A, Turesky RJ, Josephy PD. (1999). Mutat Res 428: 115-124.
34. Han XM, Ouyang DS, Chen XP, Shu Y, Jiang CH, Tan ZR et al. (2002). Br J Clin Pharmacol 54: 540-543.
35. Hankinson O. (1995). Annu Rev Pharmacol Toxicol 35: 307-340.
36. Harris JW, Katki A, Anderson LW, Chmurny GN, Paukstelis JV, Collins JM. (1994). J Med Chem 37: 706-709.
37. Hayashi S, Watanabe J, Kawajiri K. (1991). J Biochem (Tokyo) 110: 559-565.
38. Henningsson A, Marsh S, Loos WJ, Karlsson MO, Garsa A, Mross K et al. (2005). Clin Cancer Res 11: 8097-8104.
39. Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL et al. (2004). Pharmacogenetics 14: 225-238.
40. Hirth J, Watkins PB, Strawderman M, Schott A, Bruno R, Baker LH. (2000). Clin Cancer Res 6: 1255-1258.
41. Huang Z, Raychowdhury MK, Waxman DJ. (2000a). Cancer Gene Ther 7: 1034-1042.
42. Huang Z, Roy P, Waxman DJ. (2000b). Biochem Pharmacol 59: 961-972.
43. Ingelman-Sundberg M. (2004a). Naunyn-Schmiedeberg's Arch Pharmacol 369: 89-104.
44. Ingelman-Sundberg M. (2004b). Trends Pharmacol Sci 25: 193-200.
45. Ingelman-Sundberg M. (2005). Pharmacogenomics J 5: 6-13.
46. Ingelman-Sundberg M, Rodriguez-Antona C. (2005). Philos Trans R Soc Lond B Biol Sci 360: 1563-1570.
47. Jacobson PA, Green K, Birnbaum A, Remmel RP. (2002). Cancer Chemother Pharmacol 49: 461-467.
48. Jiang JG, Chen CL, Card JW, Yang S, Chen JX, Fu XN et al. (2005). Cancer Res 65: 4707-4715.
49. Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH et al. (2005). J Natl Cancer Inst 97: 30-39.
50. Johansson I, Lundqvist E, Bertilsson L, Dahl ML, Sjoqvist F, Ingelman-Sundberg M. (1993). Proc Natl Acad Sci USA 90: 11825-11829.
51. Jordan VC, Collins MM, Rowsby L, Prestwich G. (1977). J Endocrinol 76: 305-316.
52. Kaijser GP, Korst A, Beijnen JH, Bult A, Underberg WJ. (1993). Anticancer Res 13: 1311-1324.
53. Kaiser R, Sezer O, Papies A, Bauer S, Schelenz C, Tremblay PB et al. (2002). J Clin Oncol 20: 2805-2811.
54. Karlgren M, Gomez A, Stark K, Svärd J, Rodriguez-Antona C, Oliw E et al. (submitted).
55. Karlgren M, Miura S, Ingelman-Sundberg M. (2005). Toxicol Appl Pharmacol 207: 57-61.
56. Kirchheiner J, Brockmoller J. (2005). Clin Pharmacol Ther 77: 1-16.
57. Klein K, Lang T, Saussele T, Barbosa-Sicard E, Schunck WH, Eichelbaum M et al. (2005). Pharmacogenet Genomics 15: 861-873.
58. Komatsu T, Yamazaki H, Shimada N, Nakajima M, Yokoi T. (2000). Drug Metab Dispos 28: 1457-1463.
59. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J et al. (2001). Nat Genet 27: 383-391.
60. Kumarakulasingham M, Rooney PH, Dundas SR, Telfer C, Melvin WT, Curran S et al. (2005). Clin Cancer Res 11: 3758-3765.
61. Lacroix D, Sonnier M, Moncion A, Cheron G, Cresteil T. (1997). Eur J Biochem 247: 625-634.
62. Landi S, Gemignani F, Moreno V, Gioia-Patricola L, Chabrier A, Guino E et al. (2005). Pharmacogenet Genomics 15: 535-546.
63. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U et al. (2001). Pharmacogenetics 11: 399-415.
64. Lang T, Klein K, Richter T, Zibat A, Kerb R, Eichelbaum M et al. (2004). J Pharmacol Exp Ther 311: 34-43.
65. Lee SJ, Usmani KA, Chanas B, Ghanayem B, Xi T, Hodgson E et al. (2003). Pharmacogenetics 13: 461-472.
66. Leong CO, Gaskell M, Martin EA, Heydon RT, Farmer PB, Bibby MC et al. (2003). Br J Cancer 88: 470-477.
67. Li AP, Kaminski DL, Rasmussen A. (1995). Toxicology 104: 1-8.
68. Libby RT, Smith RS, Savinova OV, Zabaleta A, Martin JE, Gonzalez FJ et al. (2003). Science 299: 1578-1581.
69. Lohr M, Hoffmeyer A, Kroger J, Freund M, Hain J, Holle A et al. (2001). Lancet 357: 1591-1592.
70. Malaiyandi V, Sellers EM, Tyndale RF. (2005). Clin Pharmacol Ther 77: 145-158.
71. Martinez C, Garcia-Martin E, Blanco G, Gamito FJ, Ladero JM, Agundez JA. (2005). Br J Clin Pharmacol 59: 62-69.
72. Masson LF, Sharp L, Cotton SC, Little J. (2005). Am J Epidemiol 161: 901-915.
73. Mathijssen RH, de Jong FA, van Schaik RH, Lepper ER, Friberg LE, Rietveld T et al. (2004). J Natl Cancer Inst 96: 1585-1592.
74. Mathijssen RH, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. (2002). J Natl Cancer Inst 94: 1247-1249.
75. McFadyen MC, Breeman S, Payne S, Stirk C, Miller ID, Melvin WT et al. (1999). J Histochem Cytochem 47: 1457-1464.
76. McFadyen MC, Cruickshank ME, Miller ID, McLeod HL, Melvin WT, Haites NE et al. (2001a). Br J Cancer 85: 242-246.
77. McFadyen MC, McLeod HL, Jackson FC, Melvin WT, Doehmer J, Murray GI. (2001b). Biochem Pharmacol 62: 207-212.
78. McFadyen MC, Melvin WT, Murray GI. (2004). Mol Cancer Ther 3: 363-371.
79. Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. (2003). Neuropharmacology 45: 122-132.
80. Miyoshi Y, Ando A, Takamura Y, Taguchi T, Tamaki Y, Noguchi S. (2002). Int J Cancer 97: 129-132.
81. Miyoshi Y, Taguchi T, Kim SJ, Tamaki Y, Noguchi S. (2005). Breast Cancer 12: 11-15.
82. Murray GI, Taylor MC, McFadyen MC, McKay JA, Greenlee WF, Burke MD et al. (1997). Cancer Res 57: 3026-3031.
83. Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y et al. (2005). J Clin Pharmacol 45: 674-682.
84. Nakajima M, Kwon JT, Tanaka N, Zenta T, Yamamoto Y, Yamamoto H et al. (2001). Clin Pharmacol Ther 69: 72-78.
85. Nebert DW, Dalton TP, Okey AB, Gonzalez FJ. (2004). J Biol Chem 279: 23847-23850.
86. Nelson DR, Zeldin DC, Hoffman SM, Maltais LJ, Wain HM, Nebert DW. (2004). Pharmacogenetics 14: 1-18.
87. Niemi M, Leathart JB, Neuvonen M, Backman JT, Daly AK, Neuvonen PJ. (2003). Clin Pharmacol Ther 74: 380-387.
88. Oscarson M. (2001). Drug Metab Dispos 29: 91-95.
89. Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bernal ML et al. (1999). FEBS Lett 448: 105-110.
90. Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T et al. (2004). Front Biosci 9: 1967-1976.
91. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L et al. (2000). Pharmacogenetics 10: 373-388.
92. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, Klein EA et al. (1999). Cancer Epidemiol Biomarkers Prev 8: 901-905.
93. Potter GA, Patterson LH, Wanogho E, Perry PJ, Butler PC, Ijaz T et al. (2002). Br J Cancer 86: 774-778.
94. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, Zent R et al. (2005). J Biol Chem 280: 27138-27146.
95. Rae JM, Soukhova NV, Flockhart DA, Desta Z. (2002). Drug Metab Dispos 30: 525-530.
96. Rasmussen BB, Brix TH, Kyvik KO, Brosen K. (2002). Pharmacogenetics 12: 473-478.
97. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. (1998). J Natl Cancer Inst 90: 1225-1229.
98. Riddick DS, Lee C, Ramji S, Chinje EC, Cowen RL, Williams KJ et al. (2005). Drug Metab Dispos 33: 1083-1096.
99. Rieger MA, Ebner R, Bell DR, Kiessling A, Rohayem J, Schmitz M et al. (2004). Cancer Res 64: 2357-2364.
100. Rochat B, Morsman JM, Murray GI, Figg WD, McLeod HL. (2001). J Pharmacol Exp Ther 296: 537-541.
101. Rodriguez-Antona C, Sayi JG, Gustafsson LL, Bertilsson L, Ingelman-Sundberg M. (2005). Biochem Biophys Res Commun 338: 299-305.
102. Rooseboom M, Commandeur JN, Vermeulen NP. (2004). Pharmacol Rev 56: 53-102.
103. Roy P, Waxman DJ. (2005). Toxicol In Vitro (in press).
104. Sachse C, Brockmoller J, Bauer S, Roots I. (1999). Br J Clin Pharmacol 47: 445-449.
105. Salmons B, Lohr M, Gunzburg WH. (2003). J Gastroenterol 38(Suppl 15): 78-84.
106. Savas U, Hsu MH, Griffin KJ, Bell DR, Johnson EF. (2005). Arch Biochem Biophys 436: 377-385.
107. Sim SC, Edwards RJ, Boobis AR, Ingelman-Sundberg M. (2005b). Pharmacogenet Genomics 15: 625-631.
108. Sim SC, Risinger C, Dahl M-L, Aklillu E, Christensen M, Bertilsson L et al. (2005a). Clin Pharm Ther (in press).
109. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, Purdie DM et al. (2002). Pharmacogenetics 12: 355-366.
110. Takada K, Arefayene M, Desta Z, Yarboro CH, Boumpas DT, Balow JE et al. (2004). Arthritis Rheum 50: 2202-2210.
111. Tanaka T, Tanimoto K, Otani K, Satoh K, Ohtaki M, Yoshida K et al. (2004). Int J Cancer 111: 617-626.
112. Taniguchi R, Kumai T, Matsumoto N, Watanabe M, Kamio K, Suzuki S et al. (2005). J Pharmacol Sci 97: 83-90.
113. Tayeb MT, Clark C, Haites NE, Sharp L, Murray GI, McLeod HL. (2003). Br J Cancer 88: 928-932.
114. Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, Murray GI et al. (2002). Oncol Rep 9: 653-655.
115. Timm R, Kaiser R, Lotsch J, Heider U, Sezer O, Weisz K et al. (2005). Pharmacogenomics J 5: 365-373.
116. Tokizane T, Shiina H, Igawa M, Enokida H, Urakami S, Kawakami T et al. (2005). Clin Cancer Res 11: 5793-5801.
117. Tsuchiya K, Gatanaga H, Tachikawa N, Teruya K, Kikuchi Y, Yoshino M et al. (2004). Biochem Biophys Res Commun 319: 1322-1326.
118. Vineis P. (2002). Toxicology 181-182: 457-462.
119. Wang H, Faucette S, Sueyoshi T, Moore R, Ferguson S, Negishi M et al. (2003). J Biol Chem 278: 14146-14152.
120. Wang J, Pitarque M, Ingelman-Sundberg M. (2006). Biochem Biophys Res Commun 340: 491-497.
121. Wang J, Sönnerborg A, Rane A, Josephson F, Lundgren S, Ståhle L et al. (2005). Pharmacogenet Genomics (in press).
122. Westlind-Johnsson A, Bernhard Hauns D, Hermann R, Huennemeyer A, Lahu G, Nassr N et al. (2006). Clin Pharm Ther (in press).
123. Williams JA, Ring BJ, Cantrell VE, Jones DR, Eckstein J, Ruterbories K et al. (2002). Drug Metab Dispos 30: 883-891.
124. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M et al. (2003). Pharmacogenomics J 3: 53-61.
125. Yamamoto N, Tamura T, Murakami H, Shimoyama T, Nokihara H, Ueda Y et al. (2005). J Clin Oncol 23: 1061-1069.
126. Yasar U, Lundgren S, Eliasson E, Bennet A, Wiman B, de Faire U et al. (2002). Biochem Biophys Res Commun 299: 25-28.
127. Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE et al. (2003). Anal Biochem 316: 103-110.
128. Yu AM, Fukamachi K, Krausz KW, Cheung C, Gonzalez FJ. (2005). Endocrinology 146: 2911-2919.